SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics, today announced that it intends to offer and sell shares of its Class A common stock in an underwritten public offering (the “Offering”). Rani Therapeutics expects to grant the underwriters a 30-day option to purchase additional shares up to 15% of the aggregate number of shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.
Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock
Aug 10, 2022
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers